Many still think of ZoBio as an NMR company. And while NMR will always have a special place in our hearts, we also have a thriving crystallography team!
Detailed and timely structural information is a cornerstone of rational drug design and X-ray crystallography plays a key role in most…
Positive Impact of Dragonfly™ Discovery in Biochemical Assay
Biochemical assays are commonly used to assess how organic compounds impact the activity of a protein of interest (POI). ZoBio frequently employs biochemical assays to validate compounds that have been identified as interacting with the POI through orthogonal biophysical assays like Surface Plasmon Resonance (SPR) and Nuclear Magnetic Resonance (NMR). To enhance the efficiency and reliability of the biochemical assay workflow, ZoBio has purchased a Dragonfly™ Discovery, a valuable tool known for its ability to significantly improve assay performance by facilitating high-throughput…
Smoothening the Bumpy Road of Covalent Drug Discovery with Protein NMR
Recent years have seen a surge of interest in the use of covalent compounds in small molecule drug discovery. Much of this interest has been driven by the success of covalent compounds for “undruggable” targets such as kRAS. While it is relatively easy to buy or build a library of cysteine reactive compounds and screen them using mass spectrometry (MS), does this really provide all the information to decide whether a “hit” is a good starting point for a drug discovery campaign?
Typically, a covalent campaign starts with screening a library for conjugation…
32nd Protein Structure Determination in Industry meeting
In person Starting from Sunday, November 10th, the ZoBio team participated in the 32nd Protein Structure Determination in Industry meeting, which was held at the Novotel Paris Centre Tour Eiffel in Paris, France. This year’s meeting was organized jointly by SERVIER and Synchrotron SOLEIL, with support from Hg3 Conferences. The scientific talks focused on the…